Tandem sees big debut for super-slim insulin pump; Respiratory Motion gets FDA nod for monitor;

 @FierceMedDev: Check out our rundown of the year's biggest announced layoffs in the medical device world. More | Follow @FierceMedDev

 @MarkHFierce: BD's CFO is leaving to pursue an "entrepreneurial opportunity." More | Follow @MarkHFierce

 @DamianFierce: Biomet reduced its quarterly losses thanks to its $280M buy of DePuy's trauma unit. More | Follow @DamianFierce

> Respiratory Motion won 510(k) clearance for a new respiratory monitoring system designed to provide continuous, noninvasive minute ventilation data in non-ventilated patients. Release

> Tandem Diabetes Care is making an iPhone-like early market impression with its new t:slim insulin delivery system, the first FDA-cleared touch-screen insulin pump.  Story

> Sen. Dan Coates (R-IN) says November's presidential election is the public's only chance to do away with the medical device tax, as Mitt Romney has promised to repeal the Affordable Care Act. Editorial

> Scientists will meet in Dublin later this month for a conference designed to share advances in biomaterials research and innovation that could improve device performance. Item

> Danaher is making good on its plans to grow the company's medical diagnostics presence and shed other business lines. The company and partner Cooper will sell their hand and power tools joint venture to Bain Capital for $1.6 billion. Story

> Focus Diagnostics got 510(k) clearance for its RNA test for influenza, co-developed with 3M. News (reg. req.)

> TransMedics' Organ Care System allows lung transplants to be stored at body temperature, keeping them in better condition than if they had been cooled down during transport. Article

> The New York Times explores how iPhone and iPad apps are redefining medical devices specifically, and medicine in general. Story (sub.req.)

Biotech News

 @FierceBiotech: Diamyd Medical sells off nerve-targeted delivery unit. More | Follow @FierceBiotech

 @JohnCFierce: I'd like to see Lilly file an NDA on sola, see how regulators handle secondary analysis on data from 1 trial that couldn't be confirmed in 2nd. | Follow @JohnCFierce

 @RyanMFierce: Top counterfeit drug events in 2012 report, shows this problem affects all of us. More | Follow @RyanMFierce

> MedImmune partners on trials for a new slate of cancer immunotherapy combos. Article

> Oxford Bio shares tumble after mid-stage cancer study fizzles out. News

Pharma News

@FiercePharma: Will Optimer's plan to boost Dificid sales work? It's a volume-pricing move. More | Follow @FiercePharma

> No breakup for J&J? Goldman analyst says 'Sell'. Story

> Pfizer wraps up Celebrex suit in $164M settlement. News

Drug Delivery News

> NuPathe axes half its workforce, sells $28M of securities. Article

> Dissolving microneedles hit the sweet spot in diabetes. Item

> Diamyd Medical sells off nerve-targeted delivery unit. Story

> Smaller electric pulse hits the spot for DNA vaccines. Report

Biomarkers News

> Scratching a genetic itch in atopic dermatitis. More

> Biomarker panel spots the risk of Type 2 diabetes. Report

> Making a GENIE-us connection: Linking genes with diabetic kidney disease. Story

> Prostate cancer genetic barcodes predict aggressiveness. Article

Suggested Articles

AI-based drug molecule designer XtalPi has secured a mammoth funding round totaling $318.8 million, from global banking and tech investors.

LabCorp has licensed a blood test from Genfit designed to identify patients with risky cases of the liver disease NASH.

Philips has launched a compact, single-use device for physically clearing potentially dangerous blood clots lodged in the arms and legs.